CCNB2

G2/mitotic-specific cyclin-B2

69,978 patent compounds predicted against CCNB2, 46,948 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL490814	1.00	20/20
SCHEMBL490541	0.72	20/20
SCHEMBL490777	0.72	20/20
Kenpaullone (SCHEMBL79889)	1.00	19/20
SCHEMBL490933	1.00	19/20
SCHEMBL491100	1.00	19/20
SCHEMBL489971	1.00	18/20
SCHEMBL490489	1.00	18/20
SCHEMBL490667	1.00	18/20
SCHEMBL490671	1.00	18/20
SCHEMBL490775	1.00	18/20
SCHEMBL490811	1.00	18/20
SCHEMBL491124	1.00	18/20
Bromide (SCHEMBL490969)	0.97	18/20
SCHEMBL490088	0.63	18/20
SCHEMBL491139	0.59	18/20
Aloisine (SCHEMBL79714)	1.00	17/20
Aloisine A (SCHEMBL80147)	1.00	17/20
SCHEMBL490379	1.00	17/20
SCHEMBL490878	1.00	17/20

Germline variants in CCNB2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CCNB2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CCNB2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients	PHASE3	UNKNOWN
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer	PHASE2/PHASE3	NOT_YET_RECRUITING
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease	PHASE3	RECRUITING
Abemaciclib With or Without Atezolizumab for mCRPC	PHASE2	COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage	PHASE2	RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer	PHASE2	RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma	PHASE2	COMPLETED
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	PHASE2	COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Study of AVZO-021 in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.	PHASE1/PHASE2	COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas	PHASE2	RECRUITING
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification	PHASE2	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors	PHASE1	RECRUITING
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers	PHASE1	COMPLETED
Tamoxifen in Patients With Oesophageal Cancer	PHASE1	UNKNOWN
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	PHASE1	COMPLETED
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy	nan	UNKNOWN
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CCNB2 binder may also engage these)

Protein	Name	Similarity
Q4R7A8	—	1.000	Q4R7A8 →
P37883	—	1.000	P37883 →
P30276	—	1.000	P30276 →
Q60FY0	—	0.995	Q60FY0 →
O77689	—	0.995	O77689 →
P29332	—	0.993	P29332 →
Q92162	—	0.991	Q92162 →
Q60FX9	—	0.989	Q60FX9 →
O93229	—	0.989	O93229 →
P13350	—	0.987	P13350 →
P13351	—	0.986	P13351 →
Q9IBG1	—	0.978	Q9IBG1 →
Q9DGA0	—	0.977	Q9DGA0 →
Q9DG96	—	0.975	Q9DG96 →
Q9DGA3	—	0.973	Q9DGA3 →
Q9DG99	—	0.971	Q9DG99 →
Q9DGA4	—	0.970	Q9DGA4 →
Q9DG97	—	0.967	Q9DG97 →
Q9IBG0	—	0.966	Q9IBG0 →
P24860	—	0.962	P24860 →
P37882	—	0.960	P37882 →
P30277	—	0.959	P30277 →
Q9SA32	—	0.958	Q9SA32 →
P15206	—	0.958	P15206 →
Q1LZG6	—	0.955	Q1LZG6 →
Q01066	—	0.952	Q01066 →
F1QMB9	—	0.950	F1QMB9 →
Q61481	—	0.945	Q61481 →
Q64395	—	0.944	Q64395 →
P14100	—	0.944	P14100 →